Expiring healthcare extenders;
S. 1339, Pharmacy Benefit Manager Reform Act;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47);
Issues related to 340b
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to line extensions in the Medicaid Rebate Rule;
Issues related to Medicaid Drug Rebate Program;
S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, Lower Costs, More Transparency Act
Issues related to biosecurity
Duration: November 1, 2019
to
present
General Issues: Health Issues , Medicare/Medicaid , Homeland Security
Spending: about $930,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Tracy Spicer Deputy Chief of Staff, Political Director, Legislative Assistant,
Special Assistant, Staff Assistant - Sen. Edward Kennedy
Elizabeth Barnett Legislative Assistant, Speechwriter, Legislative Correspondent -
Sen. Blanche Lincoln; Staff Assistant - Senate Energy and Natural
Resource Committee
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Avenue Solutions lobbied for Incyte Corporation , earning $60,000. The report was filed on April 22.
Original Filing: 301574326.xml
Lobbying Issues
Expiring healthcare extenders;
S. 1339, Pharmacy Benefit Manager Reform Act;
H.R. 4366, the Consolidated Appropriations Act, 2024 (P.L. 118-42);
H.R. 2882, the Further Consolidated Appropriations Act, 2024 (P.L. 118-47);
Issues related to 340b
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to line extensions in the Medicaid Rebate Rule;
Issues related to Medicaid Drug Rebate Program;
S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act;
H.R. 5378, Lower Costs, More Transparency Act
Lobbying Issues
Issues related to biosecurity
4th Quarter, 2023
In Q4, Avenue Solutions lobbied for Incyte Corporation , earning $60,000. The report was filed on Jan. 22.
Original Filing: 301539519.xml
Lobbying Issues
Expiring healthcare extenders;
S. 1339, Pharmacy Benefit Manager Reform Act
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to healthcare access, quality and costs;
Issues related to healthcare transparency and consolidation;
Issues related to line extensions in the Medicaid Rebate Rule;
Senate Finance Committees Better Mental Health Care, Lower Cost Drugs and Extenders Act (Discussion Draft)
S. 2973, Modernizing and Ensuring PBM Accountability (MEPA) Act
H.R. 5378, Lower Costs, More Transparency Act
3rd Quarter, 2023
In Q3, Avenue Solutions lobbied for Incyte Corporation , earning $60,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511047.xml
Lobbying Issues
Issues related to 340b Drug Pricing Program;
Education around innovative therapies in dermatology;
Issues related to the White House Cancer Moonshot initiative
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to healthcare access, quality and costs;
Issues related to healthcare transparency and consolidation;
Issues related to the Medicaid Rebate Rule
2nd Quarter, 2023
In Q2, Avenue Solutions lobbied for Incyte Corporation , earning $60,000. The report was filed on July 19, 2023.
Original Filing: 301483995.xml
Lobbying Issues
Issues related to 340b Drug Pricing Program;
Education around innovative therapies in dermatology;
Issues related to the White House Cancer Moonshot initiative
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
Issues related to healthcare access, quality and costs;
Issues related to healthcare transparency and consolidation
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Avenue Solutions lobbied for Incyte Corporation , earning $60,000. The report was filed on April 20, 2023.
Original Filing: 301464299.xml
Lobbying Issues
Value of prescription drugs;
Issues related to 340b Drug Pricing Program;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Education around innovative therapies in dermatology;
Issues related to the White House Cancer Moonshot initiative
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Inflation Reduction Act of 2022 (PL 117-169) implementation;
4th Quarter, 2022
In Q4, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439689.xml
Lobbying Issues
Inflation Reduction Act of 2022 (PL 117-169) - creating Medicare negotiation of drugs, creating a new inflation rebate under Medicare, limiting insulin copays to $35/month, capping Medicare Part D premium growth, expanding premium and co-pay assistance on prescription drugs for low-income individuals, and capping Medicare out of pocket costs at $2,000 per year. , and preventing commercial spillover of maximum fair price into markets beyond Medicare;
Value of prescription drugs;
Issues related to patient assistance programs and copay accumulators;
Issues related to 340b Drug Pricing Program;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Education around innovative therapies in dermatology;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
Issues related to the White House Cancer Moonshot initiative;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act;
Executive Order Directing HHS to Explore Additional Actions to Lower Prescription Drug Costs
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413687.xml
Lobbying Issues
Issues related to H.R. 5376, Inflation Reduction Act of 2022 (now PL 117-169) and implementation;
Issues related to the Continuing Resolution, H.R. 6833;
Value of prescription drugs;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Education around innovative therapies in dermatology;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
Issues related to the FY 2023 President's Budget;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301392787.xml
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Monitor drug pricing legislation, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now; Prescription Drug Pricing Reduction Act;
Education around innovative therapies in dermatology;
H.R. 5376, Build Back Better Act;
Monitor possible health care policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of FDA user fee bills (H.R.7667, Food and Drug Amendments of 2022; S.4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
Issues related to the FY 2023 Presidents Budget;
Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act;
Senate Finance Committee bipartisan Discussion Draft: Ensuring Access to Telemental Health Services;
Senate Finance Committee bipartisan Discussion Draft: Improving Access to Physical and Mental Health Care for Children and Youth under Medicaid and CHIP;
Bipartisan Safer Communities Act, P.L. 117-159, specifically policy related to access to mental health services for youth and families through Medicaid and CHIP and telehealth;
H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on April 20, 2022.
Original Filing: 301371021.xml
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Monitor drug pricing legislation, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now; Prescription Drug Pricing Reduction Act;
Education around innovative therapies in dermatology;
H.R. 5376, Build Back Better Act;
Monitor possible health care policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
Consolidated Appropriations Act, 2022 (PL 117-103);
S. 3700/H.R. 6833, Affordable Insulin Now Act;
Issues related to reauthorization of the FDA user fee bills;
Issues related to the Public Health Emergency;
H.R. 5585, The Advanced Research Project Agency-Health (ARPA-H) Act;
Issues related to the White House Cancer Moonshot initiative;
Issues related to the FY 2023 Presidents Budget
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on Jan. 19, 2022.
Original Filing: 301329985.xml
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Monitor drug pricing legislation, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now; Prescription Drug Pricing Reduction Act;
Senate Finance Committee Prescription Drug Reform Principles;
Education around innovative therapies in dermatology;
H.R. 5376, Build Back Better Act;
Monitor possible health care policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
PL 117-58 - Infrastructure Investment and Jobs Act (BIF) - issues related to rebate rule delay, repurposed Provider Relief Funds, Medicare savings from single source vial size drug policy and extension of mandatory sequester)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Proposed repeal of the CMS Rule on Most Favored Nation Model;
PL-117-71 Protecting Medicare and American Families from Sequester Cuts Act - specifically: 6 months relief from 2% Medicare sequester, 4% statutory Pay-As-You-Go Act, 1 year relief of physician conversion factor cuts, 1 year delay of clinical lab (PAMA) cuts, delay of radiation oncology demo
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301313638.xml
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Senate Finance Committee Prescription Drug Reform Principles;
Education around innovative therapies in dermatology;
H.R. 5376, Build Back Better Act;
Monitor possible health care policies in upcoming reconciliation package including: making ACA tax credits/subsidies permanent, adding Medicare enhancements/supplemental benefits (hearing, dental, vision), addressing Medicaid coverage gap, expanding home and community based services, prescription drug reform;
Agencies Lobbied
U.S. Senate
Lobbying Issues
Proposed repeal of the CMS Rule on Most Favored Nation Model
2nd Quarter, 2021
In Q2, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301289764.xml
Lobbying Issues
Value of prescription drugs;
Issues related to Medicare Part D;
Issues related to Medicare Part B;
Implementation of American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Senate Finance Committee Prescription Drug Reform Principles;
Education around innovative therapies in dermatology
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on April 20, 2021.
Original Filing: 301262114.xml
Lobbying Issues
Education around potential COVID-19 therapies;
Value of prescription drugs;
Extension of Priority Review Voucher;
Issues related to Medicare Part D;
H.R. 1319, American Rescue Plan Act of 2021 (PL 117-2);
Continued monitoring of Consolidated Appropriations Act, 2021 (PL 116-260);
Continued monitoring of Prescription Drug Pricing Reduction Act of 2019 from 116th Congress;
Continued monitoring of Elijah E. Cummings Lower Drug Costs Now Act from 116th Congress;
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1868, To prevent across-the-board direct spending cuts, and for other purposes;
S. 748, Medicare Sequester Relief Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on Jan. 21, 2021.
Original Filing: 301244146.xml
Lobbying Issues
Education around potential COVID-19 therapies;
H.R. 133, Consolidated Appropriations Act, 2021 (Public Law 116-260);
Value of prescription drugs;
Extension of Priority Review Voucher;
Issues related to Medicare Part D
3rd Quarter, 2020
In Q3, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222959.xml
Lobbying Issues
Education around potential COVID-19 therapies;
Issues related to Priority Review Voucher extension
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on July 20, 2020.
Original Filing: 301201546.xml
Lobbying Issues
Value of prescription drugs;
Medicare Part D;
S. 2543, Prescription Drug Pricing Reduction Act of 2019;
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;
Public Law 116-136, CARES Act
1st Quarter, 2020
In Q1, Avenue Solutions lobbied for Incyte Corporation , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301170114.xml
Lobbying Issues
Value of prescription drugs;
Medicare Part D;
S. 2543, Prescription Drug Pricing Reduction Act of 2019;
H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act;
H.R. 748 (Public Law 116-136), CARES Act
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Avenue Solutions lobbied for Incyte Corporation , earning $30,000. The report was filed on Jan. 18, 2020.
Original Filing: 301120955.xml
Lobbying Issues
Value of prescription drugs;
Medicare Part D
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...